Alto Neuroscience, Inc.
ANRO · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $104,066 | $556,499 | $529,389 | $529,389 |
| - Cash | $168,229 | $82,548 | $48,344 | $25,705 |
| + Debt | $16,944 | $9,986 | $82,106 | $38,163 |
| Enterprise Value | -$47,219 | $483,937 | $563,151 | $541,847 |
| Revenue | $0 | $0 | $0 | $210 |
| % Growth | – | – | -100% | – |
| Gross Profit | -$502 | $0 | -$342 | $65 |
| % Margin | – | – | – | 31% |
| EBITDA | -$68,610 | -$34,562 | -$27,368 | -$9,042 |
| % Margin | – | – | – | -4,305.7% |
| Net Income | -$61,431 | -$36,305 | -$27,710 | -$9,187 |
| % Margin | – | – | – | -4,374.8% |
| EPS Diluted | -2.5 | -1.35 | -1.08 | -0.36 |
| % Growth | -85.2% | -25% | -200% | – |
| Operating Cash Flow | -$47,424 | -$33,448 | -$20,394 | -$9,262 |
| Capital Expenditures | -$2,075 | -$470 | -$732 | -$680 |
| Free Cash Flow | -$49,499 | -$33,918 | -$21,126 | -$9,942 |